Current Multiple Myeloma Therapy
Imaging of multiple myeloma: Current concepts
... established for diagnosis of MM [1] . CT CT allows for detection of smaller osseous lesions that are not detectable by conventional radiography [3,5] . Early changes can be detected more reliably with CT. Another ...
12
An Evolutionary Approach for Personalized Therapy in Multiple Myeloma
... and suggest an algorithm for adjusting therapeutic regimens to specific properties of the tumor burden, namely the chemosensitivity of the chemosensitive sub-population, the size, and the re-growth rate of the ...
11
Multiple Myeloma. #3071 Multiple Myeloma
... the current induction or switch and/or alter the ...Induction therapy with bortezomib-dexamethasone combination has been found to significantly improve response rates in patients undergoing autologous ...
42
RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY
... CONCLUSIONS AND TREATMENT STRATEGIES The treatment of patients with MM has moved from the era of chemotherapy to that of targeted drug therapy. This has been accompanied by improved survival outcomes. However, MM ...
10
REVIEWS. Current treatment landscape for relapsed and/or refractory multiple myeloma
... not refractory to the most recent treatment. Patients within the relapsedandrefractory MM group are defined as patients with disease relapse who have achieved minimal response (a reduction in serum or urinary Mprotein ...
13
Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches
... It should be noted that bisphosphonates and anti- RANKL therapy suppress osteoclastic bone resorption, while the proteasome inhibitors increase osteoblastic bone formation. Denosumab takes precedence over ...
6
Stem Cell Transplantation for Multiple Myeloma: Current and Future Status
... Posttransplantation therapies Despite intensive induction and tandem SCT consolidation, my- eloma recurrence occurs almost universally in patients not receiving some form of posttransplantation therapy. IFN was ...
6
Chimeric antigen receptor T cell therapy for multiple myeloma
... the current CAR constructs may not be optimal for long persistence of CAR T cells, and many researchers are trying to develop novel CAR constructs that can induce long persistence of CAR T ...
5
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
... of multiple myeloma with many new agents and combinations having been approved and being now routinely incorporated into treatment ...frontline therapy in newly diagnosed multiple ...from ...
8
Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
... Smoldering multiple myeloma risk stratification In our institution, we perform a comprehensive SMM workup (Table 2) including both PET-CT and ...the therapy, hopefully completely eradicating the ...
11
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
... of therapy Treatment prolongs survival in MM, although remissions are inevitably followed by ...that current assessment techniques may not reflect true molecular remission, even using sCR or molecular CR ...
31
Survival Analysis of Total Therapy 3 in Newly Diagnosed Multiple Myeloma
... “induction” therapy in NDxMM. Current guidelines and practice patterns routinely include between two and three drugs, with some centers utilizing up to seven anti-MM drugs for induction therapy ...
178
Multiple myeloma is the second
... ple myeloma therapy and its effects on individuals’ ...ple myeloma treatment patterns. The current study adds significantly to the literature by identifying and discussing never-ending ...
10
Lenalidomide: A new therapy for multiple myeloma
... continued therapy beyond 4 months, the dose of dexamethasone was reduced to 40 mg/day on Days 1–4 of each cycle ...primary therapy without stem cell transplantation, the CR or VGPR rate was ...with ...
9
Immunosurveillance and therapy of multiple myeloma are CD226 dependent
... Altogether, these results point toward a critical role of NK cells and CD8 + T cells in anti-CD137–mediated antimyeloma activity. Discussion Until now, the lack of reliable mouse models has limited the under- standing of ...
14
Surgical therapy of skeletal complications in multiple myeloma
... diagnosis. Multiple bone lesions, a positive bone marrow biopsy, a Salmon-Durie stage II or III and a paraproteinaemia in serum are factors predicting a poorer survival ...
5
Current Therapy of Multiple Sclerosis
... As MS therapy, mitoxantrone is given intravenously once every three months, which of course is very convenient for patients. Acute side effects are few--some hair loss and nausea for a day or two after the ...
9
Therapy for multiple myeloma historical perspective: review of literature
... for myeloma in the process of preparation for stem cell ...with myeloma, eligible for transplant were given VAD for 4 to 6 cycles and then proceeded to ...initial therapy produced overall and ...
6
Carfilzomib boosted combination therapy for relapsed multiple myeloma
... Figure 1 Depicted mechanisms of action of emerging therapies in the treatment of multiple myeloma. Abbreviations: AG, antigene; AKT, protein kinase B; APRIL, a proliferation-inducing ligand; Bcl-2, B-cell ...
13
Therapy-related leukemia/myelodysplastic syndrome in multiple myeloma
... of therapy-related malignancy have ...of therapy-related leukemia/myelodysplastic syndrome (TRL/TMDS) during the treatment of multiple myeloma ...maintenance therapy in our department ...
7